SCHEMBL18889395

SCHEMBL18889395

Cc1[nH]c2ccc(Oc3ccc(C(=O)N4CCN(CCc5ccc6c(c5)OCO6)CC4)cc3)cc2c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ DRD2 P14416 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ POLB P06746 2/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ HTT P42858 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ GFER P55789 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ GALR3 O60755 1/20 0.45
▸ TNF P01375 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ NOD1 Q9Y239 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18889391 0.93 PDE3B (0.46) KMT2AMEN1DRD2DRD3POLB
SCHEMBL18889378 0.89 SMN1; SMN2 (0.47) KMT2AMEN1DRD2DRD3POLB
SCHEMBL18889384 0.86 POLB (0.60) KMT2ADRD2DRD3POLBSMN1; SMN2
SCHEMBL18889404 0.85 POLB (0.56) KMT2AMEN1DRD2POLBSMN1; SMN2
SCHEMBL18889383 0.85 KMT2A (0.55) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL18889386 0.84 KMT2A (0.47) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL18889417 0.83 POLB (0.54) KMT2AMEN1DRD2DRD3POLB
SCHEMBL18889419 0.83 POLB (0.49) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL18919127 0.82 RXFP1 (0.56) KMT2ADRD2DRD3RXFP1SMN1; SMN2
SCHEMBL18889416 0.81 MEN1 (0.49) KMT2AMEN1DRD2DRD3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152226-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS Novogen ltd (AU) 2017-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152226-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS TPM3, TPM4, TNNI3 KMT2A 1730/4885MEN1 2944/4885DRD2 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback